Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses von Zettl, Markus, Wurm, Melanie, Schaaf, Otmar, Mostböck, Sven, Tirapu, Iñigo, Apfler, Ilse, Lorenz, Ivo C., Frego, Lee, Kenny, Cynthia, Thibodeau, Michael, Oquendo Cifuentes, Elisa, Reschke, Markus, Moll, Jürgen, Kraut, Norbert, Vogt, Anne, Sedgwick, Jonathon D., Waizenegger, Irene C.

Volltext

Abstract 4558: In vitro and in vivo characterization of the PD-1 targeting antibody BI 754091 von Zettl, Markus, Wurm, Melanie, Schaaf, Otmar, Tirapu, Iñigo, Mostböck, Sven, Reschke, Markus, Schmidbauer, Stephan-Michael, Frego, Lee, Lorenz, Ivo C., Thibodeau, Michael, Blanset, Diann, Cifuentes, Elisa Oquendo, Moll, Jürgen, Kraut, Norbert, Borges, Eric, Vogt, Anne, Sedgwick, Jonathon, Waizenegger, Irene C.

Volltext

Abstract 4547: Characterization of the LAG-3 targeting antibody BI 754111 in monotherapy and in combination with the anti-PD-1 antibody BI 754091 von Zettl, Markus, Wurm, Melanie, Schaaf, Otmar, Tirapu, Iñigo, Mostböck, Sven, Reschke, Markus, Schmidbauer, Stephan-Michael, Frego, Lee, Lorenz, Ivo C., Thibodeau, Michael, Blanset, Diann, Cifuentes, Elisa Oquendo, Moll, Jürgen, Kraut, Norbert, Borges, Eric, Vogt, Anne, Sedgwick, Jonathon, Waizenegger, Irene C.

Volltext